Palonosetron and aprepitant for prevention of postoperative nausea and vomiting in patient undergoing laparoscopic gynecology surgery.

In patients undergoing laparoscopic gynecologic surgery, which is more effective for the prevention of postoperative nausea and vomiting between palonosetron and aprepitant.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613000902796

Enrollment

100

Registered

2013-08-13

Start date

2011-10-01

Completion date

2013-09-30

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Postoperative nausea and vomiting (PONV) frequently develops in patients undergoing laparoscopic gynecologic surgery, The present study was undertaken to compare the effects of palanosetron and aprepitant on PONV in patients following laparoscopic gynecologic surgery. Patients were randomly assigned to one of two groups to receive antiemetics as follows: palanosetron 0.075 mg or aprepitant 40 mg. PONV, postoperative pain intensity, rescue antiemetics requirement, and side effects were assessed at 0, 2, 6, 24, 48 hr postoperatively.

Interventions

before 1 hour to induction of anesthesia aprepitant 40 mg was given to patients by oral

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

patients undergoing laparoscopic gynecologic surgery

Exclusion criteria

Pregnant women, 60 years of age or older and under 20 years old, weight 45kg or less, or more than 100kg, more than American society of Anesthesiologist grade three , history of previous postoperative nausea and vomiting, history of motion sickness, smokers, patient of serious cardiovascular system, kidney, liver, and hematological abnormalities.

Outcome results